References
[1] Providencia R, Elliott P, Patel K, McCready J, Babu G,
Srinivasan N, Bronis K, Papageorgiou N, Chow A, Rowland E, Lowe M, Segal
OR, Lambiase PD. Catheter ablation for atrial fibrillation in
hypertrophic cardiomyopathy: a systematic review and meta-analysis.Heart 2016;102:1533–1543
[2] Elliott P, Anastasakis A, Borger MA, Borggrefe M, Cecchi
F, Charron P, Hagege AA, Lafont A, Limongelli G, Mahrholdt H, McKenna
WJ, Mogensen J, Nihoyannopoulos P, Nistri S, Pieper PG, Pieske
B, Rapezzi C, Rutten FH, Tillmanns C, Watkins H. 2014 ESC Guidelines on
diagnosis and management of hypertrophic cardiomyopathy: the Task Force
for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the
European Society of Cardiology (ESC). Eur Heart
J . 2014;14;35:2733-2779
[3] January CT, Wann LS, Alpert JS, Calkins H, Cigarroa
JE, Cleveland JC Jr, Conti JB, Ellinor PT, Ezekowitz MD, Field
ME, Murray KT, Sacco RL, Stevenson WG, Tchou PJ, Tracy CM, Yancy
CW; ACC/AHA Task Force Members. 2014 AHA/ACC/HRS Guideline
for the Management of Patients With Atrial Fibrillation. J Am Coll
Cardiol . 2014;64;e1-e76.
[4] Steffel J, Verhamme P, Potpara TS, Albaladejo P, Antz
M, Desteghe L, Haeusler KG, Oldgren J, Reinecke H, Roldan-Schilling
V, Rowell N, Sinnaeve P, Collins R, Camm AJ, Heidbüchel H; ESC
Scientific Document Group. The 2018 European Heart Rhythm Association
Practical Guide on the use of non-vitamin K antagonist oral
anticoagulants in patients with atrial fibrillation. Eur Heart
J . 2018;39:1330-1393
[5] Zhou Y, He W, Zhou Y, Zhu W. Non-vitamin K antagonist oral
anticoagulants in patients with hypertrophic cardiomyopathy and atrial
fibrillation: a systematic review and meta-analysis. J Thromb
Thrombolysis . 2019. doi: 10.1007/s11239-019-02008-3. [Epub ahead of
print]
[6] Calkins H, Hindricks G, Cappato R, Kim YH, Saad EB, Aguinaga
L, Akar JG, Badhwar V, Brugada J, Camm J, Chen PS, Chen SA, Chung
MK, Nielsen JC, Curtis AB, Davies DW, Day JD, d’Avila A, de Groot
NMSN, Di Biase L, Duytschaever M, Edgerton JR, Ellenbogen KA, Ellinor
PT, Ernst S, Fenelon G, Gerstenfeld EP, Haines DE, Haissaguerre M, Helm
RH, Hylek E, Jackman WM, Jalife J, Kalman JM, Kautzner J, Kottkamp
H, Kuck KH, Kumagai K, Lee R, Lewalter T, Lindsay BD, Macle L, Mansour
M, Marchlinski FE, Michaud GF, Nakagawa H, Natale A, Nattel S, Okumura
K, Packer D, Pokushalov E, Reynolds MR, Sanders P, Scanavacca
M, Schilling R, Tondo C, Tsao HM, Verma A, Wilber DJ, Yamane T. 2017
HRS/EHRA/ECAS/APHRS/SOLAECE Expert Consensus Statement on Catheter and
Surgical Ablation of Atrial Fibrillation. Heart
Rhythm 2017;14:e275-e44
[7] Garg L, Sabzwari SRA, Akbar G, Ayele H, Agrawal S, Agarwal M,
Gordon J, Dusaj R, Nazir T, Bozorgnia B, Martinez M. Outcomes of cateter
ablation for atrial fibrillation in patients with hypertrophic
cardiomyopathy. J Am Coll Cardiol . 2019;73;suppl 1;478 (abstract
presented at the American Journal of Cardiology Congress 2019- 68th
Annual Scientific Sessions)
[8] Providência R, Marijon E, Albenque JP, Combes S, Combes
N, Jourda F, Hireche H, Morais J, Boveda S. Rivaroxaban and dabigatran
in patients undergoing catheter ablation of atrial fibrillation.Europace . 2014;16:1137-1144
[9] Schulman S, Kearon C; Subcommittee on Control of Anticoagulation
of the Scientific and Standardization Committee of the International
Society on Thrombosis and Haemostasis. Definition of major bleeding in
clinical investigations of antihemostatic medicinal products in
non-surgical patients. J Thromb Haemost . 2005;3:692-694
[10] Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD,
Halperin JL, Waldo AL, Ezekowitz MD, Weitz JI, Špinar J, Ruzyllo W, Ruda
M, Koretsune Y, Betcher J, Shi M, Grip LT, Patel SP, Patel I, Hanyok JJ,
Mercuri M, Antman EM. Edoxaban versus warfarin in patients with atrial
fibrillation. N Engl J Med . 2013;369:2093-2104
[11] Granger CB, Alexander JH, McMurray JJV, Lopes RD, Hylek EM,
Hanna M, Al-Khalidi HR, Ansell J, Atar D, Avezum A, Bahit MC, Diaz R,
Easton JD, Ezekowitz JA, Flaker G, Gar- cia D, Geraldes M, Gersh BJ,
Golitsyn S, Goto S, Hermosillo AG, Hohnloser SH, Horowitz J, Mohan P,
Jansky P, Lewis BS, Lopez-Sendon JL, Pais P, Parkhomenko A, Verheugt
FWA, Zhu J, Wallentin L. Apixaban versus warfarin in patients with
atrial fibrillation. New Engl J Med . 2011;365:981–992
[12] Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W,
Breithardt G, Halperin JL, Hankey GJ, Piccini JP, Becker RC, Nessel CC,
Paolini JF, Berkowitz SD, Fox KAA, Califf RM. Rivaroxaban versus
warfarin in nonvalvular atrial fibrillation. New Engl J Med.2011;365:883–891
[13] Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J,
Parekh A, Pogue J, Reilly PA, Themeles E, Varrone J, Wang S, Alings M,
Xavier D, Zhu J, Diaz R, Lewis BS, Darius H, Diener H, Joyner CD,
Wallentin L. Dabigatran versus warfarin in patients with atrial
fibrillation. New Engl J Med. 2009;361:1139–1151
[14] Jung H, Yang P, Jang E, Yu HT, Kim T, Uhm J, Kim J, Pak H, Lee
M, Joung B, Lip GYH. Effectiveness and safety of non-vitamin K
antagonist oral anticoagulants in patients with atrial fibrillation with
hypertrophic cardiomyopathy. Chest . 2019;155:354–363
[15] Dominguez F, Climent V, Zorio E, Ripoll-Vera T, Salazar-Men-
diguchía J, García-Pinilla JM, Urbano-Moral JA, Fernández- Fernández X,
Lopez-Cuenca D, Ajo-Ferrer R, Sanz-Sanchez J, Gomez-Perez Y,
López-Garrido MA, Barriales-Villa R, Gimeno JR, Garcia-Pavia P. Direct
oral anticoagulants in patients with hypertrophic cardiomyopathy and
atrial fibrillation. Int J Cardiol . 2017;248:232–238
[16] Noseworthy PA, Yao X, Shah ND, Gersh BJ (2016) Stroke and
bleeding risks in NOAC- and warfarin-treated patients with hyper-
trophic cardiomyopathy and atrial fibrillation. J Am Coll
Cardiol . 2016;67:3020–3021
[17] Lee H, Kim H, Jung J, Han K, Lee H, Park J, Kim HM, Kim Y,
Ommen SR. Novel oral anticoagulants for primary stroke prevention in
hypertrophic cardiomyopathy patients with atrial fibrillation.Stroke . 2019;50:2582–2586
[18] January CT, Wann LS, Calkins H, Chen LY, Cigarroa JE, Cleveland
JC Jr, Ellinor PT, Ezekowitz MD, Field ME, Furie KL, Heidenreich PA,
Murray KT, Shea JB, Tracy CM, Yancy CW. 2019 AHA/ACC/HRS focused update
of the 2014 AHA/ACC/HRS guideline for the management of patients with
atrial fibrillation: a report of the American College of Cardiology
Foundation/American Heart Association Task Force on Clinical Practice
Guidelines and the Heart Rhythm Society. J Am Coll Cardiol .
2019;74:104–132
[19] Creta A, Providência R, Adragao P, de Asmundis C, Chun J,
Chierchia G, Defaye P, Schmidt B, Anselme F, Finlay M, Hunter RJ,
Papageorgiou N, Lambiase PD, Schilling RJ, Combes S, Combes N, Albenque
JP, Pozzilli P, Boveda S. Impact of Type-2 Diabetes Mellitus on the
Outcomes of Catheter Ablation of Atrial Fibrillation (European
observational multicentre study). Am J of Cardiol.2020;15:901-906
[20]
Providência
R, de
Asmundis
C, Chun
J, Chierchia G, Defaye P, Anselme F, Creta A, Lambiase
PD, Schmidt
B, Chen
S, Hunter
RJ, Combes
S, Honarbakhsh
S, Combes
N, Sousa
MJ, Jebberi Z, Albenque JP, Boveda S. Catheter ablation of atrial
fibrillation in patients with heart failure with reduced ejection
fraction: Real world experience from six European centers.J
Cardiovasc Electrophysiol. 2019;30:1270-1277
[21]
Sawhney
V, Shaukat
M, Volkova
E, Jones
N, Providencia
R, Honarbakhsh
S, Dhillon
G, Chow
A, Lowe
M, Lambiase PD, Dhinoja M, Sporton S, Earley
MJ, Schilling
RJ, Hunter
RJ. Catheter ablation for atrial fibrillation on uninterrupted direct
oral anticoagulants: A safe approach.Pacing Clin
Electrophysiol. 2018;41;1001-1009
[22] Calkins H, Willems S, Gerstenfeld EP, Verma A, Schilling
R, Hohnloser SH, Okumura K, Serota H, Nordaby M, Guiver K, Biss
B, Brouwer MA, Grimaldi M; RE-CIRCUIT Investigators. Uninterrupted
Dabigatran versus Warfarin for Ablation in Atrial Fibrillation. N
Engl J Med . 2017;376:1627-1636
[23] Cappato R, Marchlinski FE, Hohnloser SH, Naccarelli GV, Xiang
J, Wilber DJ, Ma CS, Hess S, Wells DS, Juang G, Vijgen J, Hügl
BJ, Balasubramaniam R, De Chillou C, Davies DW, Fields LE, Natale
A; VENTURE-AF Investigators. Uninterrupted rivaroxaban vs. uninterrupted
vitamin K antagonists for catheter ablation in non-valvular atrial
fibrillation.
Eur Heart
J. 2015;36:1805-1811
[24] Kirchhof P, Haeusler KG, Blank B, De Bono J, Callans D, Elvan
A, Fetsch T, Van Gelder IC, Gentlesk P, Grimaldi M, Hansen J, Hindricks
G, Al-Khalidi HR, Massaro T, Mont L, Nielsen JC, Nölker G, Piccini
JP, De Potter T, Scherr D, Schotten U, Themistoclakis S, Todd D, Vijgen
J, Di Biase L. Apixaban in patients at risk of stroke undergoing atrial
fibrillation ablation. Eur Heart J . 2018;39:2942-2955
Table 1 . Demographics